FACT-ES Questionnaire

Known as: FACT-ES, Functional Assessment of Cancer Therapy-Endocrine System 
A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients experiencing specific symptoms related to… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2018
012320032018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVES A decrease in Ki67 during neoadjuvant therapy predicts response to tamoxifen. Previous trials have shown a decreased… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE To assess the effectiveness of mindfulness-based stress reduction (MBSR) for mood, breast- and endocrine-specific quality… (More)
Is this relevant?
2011
2011
BACKGROUND In patients with breast cancer (BC) undergoing systemic chemotherapy, cancer-related fatigue (CRF) is a common problem… (More)
Is this relevant?
Review
2011
Review
2011
Aromatase inhibitors (AIs) have been shown to improve disease-free survival and in certain cases, overall survival in the… (More)
Is this relevant?
2010
2010
BACKGROUND Women with breast cancer frequently undergo menopause following adjuvant chemotherapy. Here, we investigated whether… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
The study aimed to improve understanding of the natural history and impact of hot flushes after breast cancer. Data were… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2006
2006
BACKGROUND Women who receive adjuvant chemotherapy for breast cancer report fatigue, menopausal symptoms and cognitive problems… (More)
Is this relevant?
2004
2004
8001 Background: Previously we reported substantial fatigue and menopausal symptoms in 100 women receiving adjuvant chemotherapy… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE There is evidence that cognitive dysfunction, fatigue, and menopausal symptoms may occur in women receiving adjuvant… (More)
Is this relevant?
2003
2003
With the development of highly effective, well-tolerated third-generation aromatase inhibitors (AIs), these drugs will probably… (More)
Is this relevant?